Hemodynamic Instability after Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension Correlates with Cytokine Network HyperstimulationLindner J.a · Maruna P.b · Kunstyr J.c · Jansa P.d · Gürlich R.e · Kubzova K.a · Zakharchenko M.c · Linhart A.d
a2nd Surgical Department – Department of Cardiovascular Surgery, bDepartment of Pathological Physiology, cDepartment of Anesthesiology, Resuscitation and Intensive Medicine, and d2nd Medical Department of Cardiology and Angiology, General University Hospital and the First Faculty of Medicine, Charles University in Prague, and eDepartment of Vascular and Transplant Surgery, IKEM, Prague, Czech Republic
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Pulmonary endarterectomy (PEA) is an effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH). The present study tested the hypothesis that inflammation, as determined by circulating cytokine levels, may contribute to the difficulty in controlling arterial blood pressure after PEA. Materials and Methods: Thirty-six patients with CTEPH (22 males and 14 females) underwent PEA using cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest. Plasma concentrations of tumor necrosis factor α, interleukin (IL)-1β, IL-6 and IL-8 were measured repeatedly in arterial blood samples. Results: A significant correlation between norepinephrine support and IL-6 plasma concentrations was shown at the separation from CPB (k = 0.742) and 12 h after it (k = 0.801) as well as between norepinephrine support and IL-8 concentrations 12 h after the separation from CPB. Furthermore, a significant correlation was found between the cardiac index (CI) and both IL-6 and IL-8 at the separation from CPB. Conclusions: Hemodynamic instability after PEA has been associated with higher postoperative plasma concentrations of IL-6 and IL-8. The positive relation between inflammatory cytokines and CI, or cytokines and vasopressor support, is in accordance with the hypothesis that cytokine activation may be among the neurohumoral factors responsible for cardiodepression and systemic vasoplegia in CTEPH patients undergoing PEA.
© 2009 S. Karger AG, Basel
- Mayer E, Klepetko W: Techniques and outcomes of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:589–593.
- Mayer E: Surgical treatment of chronic thromboembolic pulmonary hypertension. Swiss Med Wkly 2006;136:491–497.
- Ogino H, Ando M, Matsuda H, Minatoya K, Sasaki H, Nakanishi N, Kyotani S, Imanaka H, Kitamura S: Japanese single-center experience of surgery for chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2006;82:630–636.
- Masuda M, Nakajima N: Our experience of surgical treatment for chronic pulmonary thromboembolism. Ann Thorac Cardiovasc Surg 2001;7:261–265.
- Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, Channick RN, Fedullo PF, Auger WR: Pulmonary endarterectomy: experience and lesson learned in 1,500 cases. Ann Thorac Surg 2003;76:1457–1464.
- Comini L, Pasini E, Bachetti T, Dreano M, Garotta G, Ferrari R: Acute haemodynamic effects of IL-6 treatment in vivo: involvement of vagus nerve in NO-mediated negative inotropism. Cytokine 2005;30:236–242.
- Langer F, Schramm R, Bauer M, Tscholl D, Kunihara T, Schafers HJ: Cytokine response to pulmonary thromboendarterectomy. Chest 2004;126:135–141.
- Ishida K, Kimura F, Imamaki M, Ishida A, Shimura H, Kohno H, Sakurai M, Miyazaki M: Relation of inflammatory cytokines to atrial fibrillation after off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg 2006;29:501–505.
- Parolari A, Camera M, Alamanni F, Naliato M, Polvani GL, Agrifoglio M, Brambilla M, Biancardi C, Mussoni L, Biglioli P, Tremoli E: Systemic inflammation after on-pump and off-pump coronary bypass surgery: a one-month follow-up. Ann Thorac Surg 2007;84:823–828.
- Nesher N, Frolkis I, Vardi M, Sheinberg N, Bakir I, Caselman F, Pevni D, Ben-Gal Y, Sharony R, Bolotin G, Loberman D, Uretzky G, Weinbroum AA: Higher levels of serum cytokines and myocardial tissue markers during on-pump versus off-pump coronary artery bypass surgery. J Card Surg 2006;21:395–402.
- Franke A, Lante W, Fackeldey V, Becker HP, Kurig E, Zöller LG, Weinhold C, Markewitz A: Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know? Eur J Cardiothorac Surg 2005;28:569–575.
- Ng CS, Arifi AA, Wan S, Ho AM, Wan IY, Wong EM, Yim AP: Ventilation during cardiopulmonary bypass: impact on cytokine response and cardiopulmonary function. Ann Thorac Surg 2008;85:154–162.
- Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387–389.
- Janssen SPM, Gayan-Ramirez G, Van Den Bergh A, Herijgers P, Maes K, Verbeken E, Decramer M: Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005;111:996–1005.
- Giomarelli P, Scolletta S, Borrelli E, Biagioli B: Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg 2003;76:117–123.
- Wei M, Kuukasjärvi P, Laurikka J, Kaukinen S, Honkonen EL, Metsänoja R, Tarkka M: Relation of cytokines to vasodilation after coronary artery bypass grafting. World J Surg 2003;27:1093–1098.
Martínez Rosas M: Cardiac remodeling and inflammation. Arch Cardiol Mex 2006;76:S58–S66.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.